“With our new in vitro / in vivo testing laboratory closely connected with the peptide production site, Space Pharmaceuticals provides integrated peptide drug discovery from computational prediction, peptide synthesis and laboratory testing results, forming close iterative cycles”, said Dr. Runze He, CEO at Space Pharmaceuticals.
“Operational this month, the testing facility at Xiamen National Science Park, China, is a cornerstone for our peptide discovery partnerships, enabling the most efficient and effective discovery process combining our GDBspace drug discovery engine with on-demand high-quality peptide production and experimental data generation for feedback loops”, said Dr. Jingwen Shi, Chief Business Officer at Space Pharmaceuticals, responsible for the company’s drug discovery partnerships.